肿节风注射液辅助治疗晚期食道癌的疗效及对患者血清VEGF、S100A4水平的影响

目的:探讨肿节风注射液辅助治疗晚期食道癌的疗效及对患者血清血管内皮细胞生长因子(VEGF)、钙结合蛋白S100A4(S100A4)水平的影响。方法:选取2015年12月～2018年12月我院收治的晚期食道癌患者61例,采用随机数字表法将患者分为两组。对照组患者采用TP方案进行化疗,观察组在对照组的基础上给予肿节风注射液。比较两组患者的临床治疗效果,治疗前后的症状积分、生存质量评分和血清VEGF、S100A4水平的变化以及不良反应的发生情况。结果:治疗后,观察组总有效率和疾病控制率分别为93.55%、87.1%,均显著高于对照组(70%、60%,P0.05)。两组患者治疗后的症状积分、血清VEGF、S100A4水平均较治疗前显著下降,且观察组以上指标均显著低于对照组(P0.05)。对照组患者治疗后的生存质量评分明显下降,而观察组生存质量评分较治疗前无明显变化,但显著高于对照组(P0.05)。两组患者白细胞减少、血小板减少、贫血、恶心呕吐及肝肾功能异常等不良反应发生率比较差异无统计学意义(P0.05)。结论:肿节风注射液联合化疗可显著提高晚期食道癌患者的临床疗效,改善患者的生存质量,可能与其有效降低患者血清VEGF、S100A4水平有关。

Clinical Efficacy of Zhongjiefeng Injection in the Treatment of Patients with Advanced Esophageal Cancer and Its Effect on the Serum VEGF and S100A4 Levels

ABSTRACT Objective: To investigate the curative effect of zhongjiefeng injection in the treatment of advanced esophageal cancer and its effect on the serum VEGF and S100A4 levels. Methods: 61 patients with advanced esophageal cancer admitted to our hospital from December 2015 to December 2018 were selected. The patients were divided into two groups by the random number table method. Patients in the control group were given chemotherapy with TP, while patients in the observation group were given zhongjiefeng injection on the basis of control group. The clinical efficacy, symptom score, quality of life score, changes of serum VEGF and S100A4 and adverse reactions before and after treatment were compared between the two groups. Results: After treatment, the total effective rate and disease control rate in the observation group were 93.55% and 87.1%, respectively, which were significantly higher than those in the control group (70%, 60%, P<0.05). The symptom scores, serum VEGF and S100A4 levels of the two groups of patients after treatment were significantly lower than those before treatment, and the above indicators in the observation group were significantly lower than those in the control group (P<0.05). The quality of life score of patients in the control group decreased significantly after treatment, which showed no significant change in the observation group before and after treatment, but it was significantly higher than that in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions including leukopenia, thrombocytopenia, anemia, nausea and vomiting, and liver and kidney dysfunction between the two groups (P>0.05). Conclusion: Zhong-jiefeng injection combined with chemotherapy can significantly improve the clinical efficacy and quality of life of patients with advanced esophageal cancer, which may be related to its effective reduction of serum VEGF and S100A4 levels.